FDA approved the first rapid-acting biosimilar insulin product, Merilog (insulin-aspart-szij), a biosimilar to its reference product Novolog (insulin aspart), to improve glycemic control in adults and children with diabetes mellitus.
Similar Posts
Certification Process for Designated Medical Gases
This guidance explains how FDA administers the certification process and describes the annual reporting requirements for designated medical gases (DMGs).BRS Analytical Services, LLC – 711133 – 09/17/2025
CGMP/Finished Pharmaceuticals/AdulteratedCurrent Good Manufacturing Practice for Medical Gases
Pharmaceutical Quality/Manufacturing Standards (CGMP)FDA’s ISTAND Pilot Program accepts submission of first artificial intelligence-based and digital health technology for neuroscience
FDA’s Center for Drug Evaluation and Research (CDER) recently accepted a new submission into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program. This submission is the first artificial intelligence-based and digital health technology-based project and the first proHuman Drug Compounding
Compounded drugs can serve an important medical need for certain patients, they also present a risk to patients.Mericon Industries, Inc. – 692733 – 07/17/2025
Unapproved New Drugs/Misbranded